Hjem › Leverkreft (hepatocellulært karcinom) › New Jersey
Kliniske studier for Leverkreft (hepatocellulært karcinom) i New Jersey
10 studier for Leverkreft (hepatocellulært karcinom) søker deltakere på steder i New Jersey.
Byer i New Jersey
Offisiell studietekst (engelsk)
A Study of ZW251 in Participants With Advanced Solid Tumors
- Hackensack University Medical Center, Hackensack
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT07164313Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #88, East Brunswick
- Exelixis Clinical Site #105, Hackensack
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05176483A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07291076Evaluating Novel Therapies in ctDNA Positive GI Cancers
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05482516Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, New Brunswick
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06921785First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Research Site, Hackensack
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. aug. 2026 · NCT06795022A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Overlook Medical Center, Summit
RekruttererFase 2
Alder 8 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05503797Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
- Rutgers Cancer Institute of New Jersey, New Brunswick
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 20. jan. 2026 · NCT05366829SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, New Brunswick
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy
- Englewood Hospital, Englewood
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jul. 2025 · NCT06681818Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.